Colorectal adenomas: A prototype for the use of surrogate end points in the development of cancer prevention drugs

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3908-3918

  Kelloff, Gary J ^a   Schilsky, Richard L ^b   Alberts, David S ^c   Day, Robert W ^d   Guyton, Kathryn Z ^e   Pearce, Homer L ^f   Peck, Jonathan C ^g   Phillips, Robert ^h   Sigman, Caroline C ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e CCS Associates   (United States)

^f ELI LILLY AND COMPANY   (United States)

^g Virginia USA   (United States)

^h Ontario Cancer Biomarker Network   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CALCIUM; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; FOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; URSODEOXYCHOLIC ACID;

ACUTE KIDNEY FAILURE; ADENOMA; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER SIZE; COLORECTAL ADENOMA; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDEMA; GALLSTONE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERTENSION; LIVER TOXICITY; MORBIDITY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN TOXICITY;

ADENOMA; BIOLOGICAL MARKERS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DRUG DESIGN; HUMANS; RESEARCH DESIGN;

EID: 2542536944     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0789     Document Type: Review

References (133)

1. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002;8:314-46.
2. Metz DC, Alberts DS. Gastrointestinal cancer prevention in the united states: the road ahead. Cancer Epidemiol Biomark Prev 2003;12: 81-3.
3. Kelloff GJ, Sigman CC, Johnson KM, et al. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomark Prev 2000;9:127-37.
4. Boone CW, Kelloff GJ. Prevention of cancer in the next millennium: report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res 1999;59:4743-58.
5. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science (Wash DC) 1997;278:1073-7.
6. Quantitative pathology in chemoprevention trials: standardization and quality control of surrogate endpoint biomarker assays for colon, breast and prostate. New York: Wiley-Liss, 1994.
7. Boone CW, Kelloff GJ, Steele VE. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res 1992;52:1651-9.
8. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
9. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Eng J Med 1988;319:525-32.
10. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002;3:101-28.
11. Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD. Detection of aberrantly methylated hmlh1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001;61:900-2.
12. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science (Wash DC) 2003;299:1753-5.
13. MacDonald JS. Carcinoembryonic antigen screening: Pros and cons. Semin Oncol 1999;26:556-60.
14. Ahlquist DA. Stool-based DNA tests for colorectal cancer: clinical potential and early results. Rev Gastroenterol Disord 2002;2(Suppl 1):S20-6.
15. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta 2002;315:157-68.
16. Shpitz B, Hay K, Medline A, et al. Natural history of aberrant crypt foci. A surgical approach. Dis Colon Rectum 1996;39:763-7.
17. Pretlow TP, Brasitus TA, Fulton NC, Cheyer C, Kaplan EL. K-ras mutations in putative preneoplastic lesions in human colon. J Natl Cancer Inst (Bethesda) 1993;85:2004-7.
18. Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998; 339:1277-84.
19. Lockhart-Mummery JP, Dukes C. The precancerous changes in the rectum and colon. Surg Gynecol Obstet 1928;XLVI:591-6.
20. Morson BC. Some leads to the etiology of cancer of the large bowel. Proc R Soc Med 1971;64:959-62.
21. Morson B. President's address. The polyp-cancer sequence in the large bowel. Proc R Soc Med 1974;67:451-7.
22. Morson BC. Evolution of cancer of the colon and rectum. Proc Inst Med Chic 1974;30:145-8.
23. Morson BC. Genesis of colorectal cancer. Clin Gastroenterol 1976; 5:505-25.
24. Stryker SJ, Wolff BG, Culp CE, et al. Natural history of untreated colonic polyps. Gastroenterology 1987;93:1009-13.
25. O'Brien MJ, Winawer SJ, Zauber AG, et al. The national polyp study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990;98:371-9.
26. Tobi M. Polyps as biomarkers for colorectal neoplasia. Front Biosci 1999;4:D329-38.
27. Kozuka S, Nogaki M, Ozeki T, Masumori S. Premalignancy of the mucosal polyp in the large intestine. II. Estimation of the periods required for malignant transformation of mucosal polyps. Dis Colon Rectum 1975;18:494-500.
28. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977-81.
29. Winawer SJ, Zauber AG, O'Brien MJ, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 1993;328:901-6.
30. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992;326:653-7.
31. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. Effect of fecal occult blood testing on mortality from colorectal cancer. A case-control study. Ann Intern Med 1993;118:1-6.
32. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst (Bethesda) 1992;84:1572-5.
33. Muller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med 1995;123:904-10.
34. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326:658-62.
35. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA-Cancer J Clin 2004;54:8-29.
36. From the Centers for Disease Control and Prevention. Trends in screening for colorectal cancer-United States, 1997 and 1999. JAMA 2001;285:1570-1.
37. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
38. Cannon-Albright LA, Skolnick MH, Bishop DT, Lee RG, Burt RW. Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal cancers. N Engl J Med 1988;319:533-7.
39. Collett JA, Platell C, Fletcher DR, Aquilia S, Olynyk JK. Distal colonic neoplasms predict proximal neoplasia in average-risk, asymptomatic subjects. J Gastroenterol Hepatol 1999;14:67-71.
40. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
41. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
42. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer (Phila) 1994;74:1847-54.
43. Greenberg ER, Baron JA, Freeman DH, Mandel JS, Haile R. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst (Bethesda) 1993;85:912-6.
44. Logan RF, Little J, Hawtin PG, Hardcastle JD. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham Faecal Occult Blood Screening Programme. Br Med J 1993;307:285-9.
45. Martinez ME, McPherson RS, Levin B, Annegers JF. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Biomark Prev 1995;4:703-7.
46. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst (Bethesda) 1993;85:1220-4.
47. Villavicencio RT, Rex DK. Colonic adenomas: prevalence and incidence rates, growth rates, and miss rates at colonoscopy. Semin Gastrointest Dis 2000;11:185-93.
48. Number of ambulatory and inpatient procedures by procedure category and location: United States, 1996. Vital and Health Statistics, Series 13, No. 139, 1998.
49. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst (Bethesda) 1999;91:916-32.
50. Kinzler KW, Nilbert MC, Su LK, et al. Identification of FAP locus genes from chromosome 5q21. Science (Wash DC) 1991;253:661-5.
51. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66:589-600.
52. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-TCF signaling in colon cancer by mutations in beta-catenin or APC. Science (Wash DC) 1997;275:1787-90.
53. Morin PJ. Beta-catenin signaling and cancer. Bioessays 1999;21: 1021-30.
54. Lynch HT, Lynch JF. Hereditary nonpolyposis colorectal cancer. Semin Surg Oncol 2000;18:305-13.
55. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999;340:101-7.
56. Wu K, Willett WC, Fuchs CS, Colditz GA, Giovannucci EL. Calcium intake and risk of colon cancer in women and men. J Natl Cancer Inst (Bethesda) 2002;94:437-46.
57. Summary minutes of the Gastrointestinal Drugs Advisory Committee meeting, March 19 2002. http://www.fda.gov/ohrms/dockets/ac/02/minutes/3845M1.htm.CDER/FDA. Accessed February 9, 2004.
58. Transcript of the Gastrointestinal Drugs Advisory Committee meeting, March 19 2002. http://www.fda.gov/ohrms/dockets/ac/02/transcripts/3845tl.htm. CDER/FDA. Accessed February 9, 2004.
59. Walsh JM, Terdiman JP. Colorectal cancer screening: Scientific review. JAMA 2003;289:1288-96.
60. Atkin WS. Screening for colorectal cancer: the heart of the matter. Gut 1999;45:480-1.
61. Gatto NM, Frucht H, Sundararajan V, et al. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst (Bethesda) 2003;95:230-6.
62. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105:31S-8S.
63. Bjorkman DJ. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am J Med 1999;107:3S-8S;discussion 8S-108.
64. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst (Bethesda) 2001;93:684-90.
65. O'Neill RT. Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studies. Stat Med 1998;17:1851-8;discussion 1859-62.
66. Ajayi FO, Sun H, Perry J. Adverse drug reactions: a review of relevant factors. J Clin Pharmacol 2000;40:1093-101.
67. Smith RA, Mettlin CJ, Davis KJ, Eyre H. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. CA-Cancer J Clin 2001;51:38-75.
68. Rex DK, Johnson DA, Lieberman DA, Burt RW, Sonnenberg A. Colorectal cancer prevention 2000: screening recommendations of the American College of Gastroenterology. American College of Gastroenterology. Am J Gastroenterol 2000;95:868-77.
69. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
70. Anderson WF, Guyton KZ, Hiatt RA, et al. Colorectal cancer screening for persons at average risk. J Natl Cancer Inst (Bethesda) 2002;94:1126-33.
71. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
72. Hawk E, Viner JL, Umar A, et al. Cancer and the cyclooxygenase enzyme: implications for treatment and prevention. Am J Cancer 2003; 2:27-55.
73. Howe LR, Dannenberg AJ. A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol 2002;29:111-9.
74. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
75. Kargman SL, O'Neill GP, Vickers PJ, et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556-9.
76. Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996;93:4816-20.
77. Gustafson-Svard C, Lilja I, Hallbook O, Sjodahl R. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut 1996;38:79-84.
78. Fujita T, Matsui M, Takaku K, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998;58:4823-6.
79. Maekawa M, Sugano K, Sano H, et al. Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. Jpn J Clin Oncol 1998;28:421-6.
80. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282:1254-7.
81. Dimberg J, Samuelsson A, Hugander A, Soderkvist P. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 1999; 45:730-2.
82. Tomozawa S, Tsuno NH, Sunami E, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000;83:324-8.
83. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996;56:4566-9.
84. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-12.
85. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-4.
86. Sasai H, Masaki M, Wakitani K. Suppression of polypogenesis in a new mouse strain with a truncated APC(delta474) by a novel COX-2 inhibitor, JTE-522. Carcinogenesis (Lond) 2000;21:953-8.
87. Yoshimi N, Shimizu M, Matsunaga K, et al. Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane. Jpn J Cancer Res 1999;90:406-12.
88. Yoshimi N, Kawabata K, Hara A, et al. Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of f344 rats. Jpn J Cancer Res 1997;88:1044-51.
89. Fukutake M, Nakatsugi S, Isoi T, et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis (Lond)1998; 19:1939-42.
90. Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the APCdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001;61:1733-40.
91. Lal G, Ash C, Hay K, et al. Suppression of intestinal polyps in MSH2-deficient and non-MSH2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res 2001;61:6131-6.
92. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988;48:4399-404.
93. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.
94. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
95. Garcia-Rodriguez LA, Heuerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 2001;12:88-93.
96. Giovannucci E. The prevention of colorectal cancer by aspirin use. Biomed Pharmacother 1999;53:303-8.
97. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst (Bethesda) 2002;94:252-66.
98. Hawk E, Lubet R, Limburg P. Chemoprevention in hereditary colorectal cancer syndromes. Cancer (Phila) 1999;86:2551-63.
99. Higuchi T, Iwama T, Yoshinaga K, et al. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003;9:4756-60.
100. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
101. Phillips RK, Wallace MH, Lynch PM, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50:857-60.
102. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99. Erratum in: N Engl J Med 1999;341:548.
103. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99. Erratum in: N Engl J Med 1999;341:548.
104. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA 2000;284:1247-55.
105. Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000;7:159-75.
106. Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000;35:937-40.
107. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature (Lond) 1995;378:406-9.
108. Komhoff M, Wang JL, Cheng HF, et al. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int 2000;57:414-22.
109. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343: 1520-8.
110. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163:481-6.
111. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
112. Mersfelder TL, Stewart LR. Warfarin and celecoxib interaction. Ann Pharmacother 2000;34:325-7.
113. Haase KK, Rojas-Fernandez CH, Lane L, Frank DA. Potential interaction between celecoxib and warfarin. Ann Pharmacother 2000; 34:666-7.
114. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002;36:525-31.
115. Clinical development plan: Ursodiol. J Cell Biochem Suppl 1996; 26:258-68.
116. Narisawa T, Fukaura Y, Terada K, Sekiguchi H. Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats. Jpn J Cancer Res 1998;89:1009-13.
117. Narisawa T, Fukaura Y, Terada K, Sekiguchi H. Inhibitory effects of ursodeoxycholic acid on N-methylnitrosourea-induced colon carcinogenesis and colonic mucosal telomerase activity in F344 rats. J Exp Clin Cancer Res 1999;18:259-66.
118. Narisawa T, Fukaura Y, Takeba N, Nakai K. Chemoprevention of N-methylnitrosourea-induced colon carcinogenesis by ursodeoxycholic acid-5-aminosalicylic acid conjugate in F344 rats. Jpn J Cancer Res 2002;93:143-50.
119. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95.
120. Powell AA, LaRue JM, Batta AK, Martinez JD. Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells. Biochem J 2001;356:481-6.
121. Qiao D, Im E, Qi W, Martinez JD. Activator protein-1 and CCAAT/enhancer-binding protein mediated GADD153 expression is involved in deoxycholic acid-induced apoptosis. Biochim Biophys Acta 2002;1583:108-16.
122. Qiao D, Stratagouleas ED, Martinez JD. Activation and role of mitogen-activated protein kinases in deoxycholic acid-induced apoptosis. Carcinogenesis (Lond) 2001;22:35-41.
123. Jenkins JK, Boothby LA. Treatment of itching associated with intrahepatic cholestasis of pregnancy. Ann Pharmacother 2002; 36:1462-5.
124. Serfaty L, De Leusse A, Rosmorduc O, et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 2003;38:203-9.
125. Alberts DS, Martinez ME, Roe D, et al. Proving the bile acid hypothesis for colon carcinogenesis: mature results from a Phase III chemoprevention trial of ursodeoxycholic acid versus placebo to prevent colorectal adenoma recurrence. Proc Am Soc Clin Oncol 2003;22:91.
126. Schernhammer ES, Kang JH, Chan AT, et al. A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst (Bethesda) 2004;96:22-8.
127. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
128. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
129. Yamada Y, Mori H. Pre-cancerous lesions for colorectal cancers in rodents: a new concept. Carcinogenesis (Lond) 2003;24:1015-9.
130. Hao XP, Pretlow TG, Rao JS, Pretlow TP. Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res 2001;61: 8085-8.
131. Luo L, Li B, Pretlow TP. DNA alterations in human aberrant crypt foci and colon cancers by random primed polymerase chain reaction. Cancer Res 2003;63:6166-9.
132. Kelloff GJ, Hawk ET, Crowell JA, et al. Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology (Huntingdon) 1996;10:1471-84;discussion 1484-8.
133. Ilyas M, Straub J, Tomlinson IP, et al. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999;35:335-51.